Cancer Research and Treatment

Original Articles

General

Estimation of Population Attributable Fraction by Hormone and Reproductive Factors on Female Cancer in the Republic of Korea, 2015 to 2030: Youjin Hong, Soseul Sung, Woojin Lim, Sungji Moon, Kwang-Pil Ko, Jung Eun Lee, Inah Kim, Sun Ha Jee, Sun-Seog Kweon, Min-Ho Shin, Sangmin Park, Seung-Ho Ryu, Sun Young Yang, Jeongseon Kim, Sang-Wook Yi, Yoon-Jung Choi, Jeong-Soo Im, Hong Gwan Seo, Sue K. Park; Cancer Res Treat. 2025;57(3):649-658. Published online November 19, 2024; DOI: https://doi.org/10.4143/crt.2024.707

Abstract PDF Supplementary Material PubReader ePub

Purpose
Population attributable fractions (PAFs) for hormone and reproductive factors have been estimated in several countries. International Agency for Research on Cancer (IARC) designated as group 1 and group 2A carcinogen for hormone factors in breast, ovarian, endometrial and uterine cervix cancer. This study aimed to estimate the PAFs of hormone/reproductive factor attributed to cancer incidence and deaths in Korean women and projected trends from 2015 to 2030.
Materials and Methods
The PAF was estimated with using the 2005 standardized prevalence rates and 2020 incidence and deaths with a 15-year latency. Based on the Levin’s formula, prevalence rates were calculated using the Korea National Health and Nutrition Examination Survey (KNHANES) and the relative risks, which were the risk of selected female cancer associated with oral contraceptive, hormone replacement therapy and duration of breastfeeding, were estimated from the meta-analysis of studies performed in Korean women population. Studies based on the Asian and Global populations were calculated as a sensitivity analysis.
Results
The estimation PAFs for hormone was 1.02% with 1,192 cases and reproductive was 2.67% with 3,112 cases. Moreover, 0.40% (125 deaths) and 1.09% (342 deaths) in female-related cancer deaths in order. Estrogen-progesterone combined hormone replacement therapy (HRT) accounted the most proportion in hormone factors and breastfeeding in reproductive factors. Also, the breast cancer had the highest percent in both hormone and reproductive factors.
Conclusion
Through this study, 1.02% and 2.67% of female-related cancer incidence will be reduced by encouraging avoiding the use of oral contraceptives and HRT and breastfeeding for more than 6 months in reproductive factors. Additionally, among four selected female cancers in this study, breast cancer was observed to be a significant level of prevention.

Citations

Citations to this article as recorded by

Application and interpretation of attributable fraction measures from clinical practice to policy: a narrative review
Sue Kyung Park
Journal of the Korean Medical Association.2026; 69(5): 411. CrossRef
Fraction of cancer incidence and mortality attributable to dietary factors in Korea from 2015 to 2030
Hyun Jeong Cho, Jin Young Yoo, Ga-Eun Yie, An Na Kim, Soseul Sung, Sungji Moon, Youjin Hong, Sangjun Lee, Inah Kim, Kwang-Pil Ko, Sun-Seog Kweon, Jung Eun Lee, Sue K. Park
Epidemiology and Health.2025; 47: e2025065. CrossRef

5,930 View
188 Download
1 Web of Science
2 Crossref

Gastrointestinal Cancer

Association between ALDH2 and ADH1B Polymorphisms and the Risk for Colorectal Cancer in Koreans: Chang Kyun Choi, Min-Ho Shin, Sang-Hee Cho, Hye-Yeon Kim, Wei Zheng, Jirong Long, Sun-Seog Kweon; Cancer Res Treat. 2021;53(3):754-762. Published online December 24, 2020; DOI: https://doi.org/10.4143/crt.2020.478

Abstract PDF PubReader ePub

Purpose
Excessive alcohol consumption has been linked to an increased risk of colorectal cancer (CRC). We evaluated the association between alcohol-related genetic variants and CRC risk.
Materials and Methods
The study cohort consisted of 5,435 CRC cases and 3,553 population-based cancer-free controls. Genotype data were generated from germline DNA using the Infinium OncoArray-500K BeadChip in 2,535 cases and 2,287 controls and the Infinium Multi-Ethnic Global BeadChip in 2,900 cases and 1,266 controls. The associations between aldehyde dehydrogenase 2 (ALDH2) rs671 and alcohol dehydrogenase 1B (ADH1B) rs1229984 polymorphisms and CRC risk were assessed using multivariate logistic regression analyses.
Results
Compared with the major homozygous ALDH2 genotype (GG), heterozygous or minor homozygous ALDH2 genotype (GA or AA, related to a low alcohol consumption) was significantly associated with a reduced risk for CRC in men (odds ratio [OR], 0.78; 95% confidence interval [CI], 0.68 to 0.90), but not in women (OR, 0.70; 95% CI, 0.47 to 1.05). A stronger association was found among regular drinkers (OR, 0.58; 95% CI, 0.47 to 0.71 in men and OR, 0.33; 95% CI, 0.18 to 0.58 in women). No association of CRC risk with ADH1B rs1229984 genotype was found. The association between alcohol-related combined genotypes and risk of CRC was significant (p for linear=0.001). The combined genotype with the highest genetically predicted alcohol consumption (ALDH2 rs671 GG and ADH1B rs1229984 AG/GG) was associated with a high risk for CRC (OR, 1.35; 95% CI, 1.11 to 1.63).
Conclusion
Our study provides strong evidence for a possible causal association between alcohol consumption and CRC risk.

Citations

Citations to this article as recorded by

ADH1B acts as a tumor suppressor in hepatocellular carcinoma: evidence from multi-omics integration and experimental validation
Fang-Cheng Jiang, Xin-Min Liang, Zhi-Heng Chen, Ye-Hui He, Jiao-Jiao Chen, Harivignesh Murugesan, Zhen-Bo Feng, Li Gao
European Journal of Medical Research.2026;[Epub] CrossRef
ADH1B regulates tumor stemness by activating the cAMP/PKA/CREB1 signaling axis to inhibit recurrence and metastasis of lung adenocarcinoma
Hairong Shi, Youtao Xu, Guoxin Song, Tianzhu Qiu
Biochemical and Biophysical Research Communications.2025; 760: 151681. CrossRef
Alcohol-Metabolizing Enzymes, Liver Diseases and Cancer
Tao Liu, FeiYu Zhang, Yue Feng, PanShiLi Han, YanHang Gao
Seminars in Liver Disease.2025; 45(01): 099. CrossRef
Genetic Polymorphisms of ALDH2 and ADH1B in Alcohol-Induced Liver Injury: Molecular Mechanisms of Inflammation and Disease Progression in East Asian Populations
Tomoko Tadokoro, Kyoko Oura, Mai Nakahara, Koji Fujita, Joji Tani, Asahiro Morishita, Hideki Kobara
International Journal of Molecular Sciences.2025; 26(17): 8328. CrossRef
Establishment and validation of a prognostic model based on vasculogenic mimicry-related gene clustering in ovarian cancer
Xueyuan Zhao, Yan Jia, Weijia Wen, Caixia Shao, Qiaojian Zou, Linna Chen, Hongye Jiang, Guofen Yang, Wei Wang, Chunyu Zhang, Shuzhong Yao
Frontiers in Oncology.2025;[Epub] CrossRef
Potentially functional genetic variants in interferon regulatory factor family genes are associated with colorectal cancer survival
Xiaoxia Tong, Chenghui Li, Li Ma, Di Wu, Yonglei Liu, Liqin Zhao, Mengyun Wang
Molecular Carcinogenesis.2024; 63(9): 1669. CrossRef
Impacts of ADH1B rs1229984 and ALDH2 rs671 polymorphisms on risks of alcohol‐related disorder and cancer
Ting‐Gang Chang, Ting‐Ting Yen, Chia‐Yi Wei, Tzu‐Hung Hsiao, I‐Chieh Chen
Cancer Medicine.2023; 12(1): 747. CrossRef
TP73-AS1 rs3737589 Polymorphism is Associated With the Clinical Stage of Colorectal Cancer
Yichang Gao, Shulong Zhang, Xueren Gao, Vijaya Anand
Evidence-Based Complementary and Alternative Medicine.2023;[Epub] CrossRef
Identifying and analyzing the key genes shared by papillary thyroid carcinoma and Hashimoto’s thyroiditis using bioinformatics methods
Ting-ting Liu, De-tao Yin, Nan Wang, Na Li, Gang Dong, Meng-fan Peng
Frontiers in Endocrinology.2023;[Epub] CrossRef
No association between genetically predicted C-reactive protein levels and colorectal cancer survival in Korean: two-sample Mendelian randomization analysis
Chang Kyun Choi, Jung-Ho Yang, Min-Ho Shin, Sang-Hee Cho, Sun-Seog Kweon
Epidemiology and Health.2023; 45: e2023039. CrossRef
Genetically determined alcohol consumption and cancer risk in Korea
Keum Ji Jung, Ji Woo Baek, Sang Yop Shin, Sun Ha Jee
Epidemiology and Health.2023; 45: e2023077. CrossRef
Dysregulated Expression of Three Genes in Colorectal Cancer Stratifies Patients into Three Risk Groups
Alba Rodriguez, Luís Antonio Corchete, José Antonio Alcazar, Juan Carlos Montero, Marta Rodriguez, Luis Miguel Chinchilla-Tábora, Rosario Vidal Tocino, Carlos Moyano, Saray Muñoz-Bravo, José María Sayagués, Mar Abad
Cancers.2022; 14(17): 4076. CrossRef
Alcohol metabolism genes and risks of site‐specific cancers in Chinese adults: An 11‐year prospective study
Pek Kei Im, Ling Yang, Christiana Kartsonaki, Yiping Chen, Yu Guo, Huaidong Du, Kuang Lin, Rene Kerosi, Alex Hacker, Jingchao Liu, Canqing Yu, Jun Lv, Robin G. Walters, Liming Li, Zhengming Chen, Iona Y. Millwood
International Journal of Cancer.2022; 150(10): 1627. CrossRef
The Roles of Drug Metabolism-Related ADH1B in Immune Regulation and Therapeutic Response of Ovarian Cancer
Zhijie Xu, Bi Peng, Fanhua Kang, Wenqin Zhang, Muzhang Xiao, Jianbo Li, Qianhui Hong, Yuan Cai, Wei Liu, Yuanliang Yan, Jinwu Peng
Frontiers in Cell and Developmental Biology.2022;[Epub] CrossRef
Alcoholic liver disease: a new insight into the pathogenesis of liver disease
Seol Hee Park, Young-Sun Lee, Jaemin Sim, Seonkyung Seo, Wonhyo Seo
Archives of Pharmacal Research.2022; 45(7): 447. CrossRef
MMP2 Polymorphisms and Colorectal Cancer Susceptibility in a Chinese Han Population
Xu Liu, Kelaier Yang, Zhangfu Li, Jikui Liu
International Journal of General Medicine.2022; Volume 15: 6009. CrossRef
ALDH2 gene rs671 G > a polymorphism and the risk of colorectal cancer: A hospital‐based study
Zhuoxin Zhang, Yijin Chen, Qingqing Zhuo, Changqing Deng, Yang Yang, Wen Luo, Shixun Lai, Hui Rao
Journal of Clinical Laboratory Analysis.2022;[Epub] CrossRef

12,967 View
200 Download
18 Web of Science
17 Crossref

Immunogenicity and Optimal Timing of 13-Valent Pneumococcal Conjugate Vaccination during Adjuvant Chemotherapy in Gastric and Colorectal Cancer: A Randomized Controlled Trial: Wonyoung Choi, Jong Gwang Kim, Seung-Hoon Beom, Jun-Eul Hwang, Hyun-Jung Shim, Sang-Hee Cho, Min-Ho Shin, Sin-Ho Jung, Ik-Joo Chung, Joon Young Song, Woo Kyun Bae; Cancer Res Treat. 2020;52(1):246-253. Published online July 9, 2019; DOI: https://doi.org/10.4143/crt.2019.189

Abstract PDF Supplementary Material PubReader ePub

Purpose
Pneumococcal vaccination (13-valent pneumococcal conjugate vaccine [PCV13]) is recommended to cancer patients undergoing systemic chemotherapy. However, the optimal time interval between vaccine administration and initiation of chemotherapy has been little studied in adult patients with solid malignancies.
Materials and Methods
We conducted a prospective randomized controlled trial to evaluate whether administering PCV13 on the first day of chemotherapy is non-inferior to vaccinating 2 weeks prior to chemotherapy initiation. Patients were randomly assigned to two study arms, and serum samples were collected at baseline and 4 weeks after vaccination to analyze the serologic response against Streptococcus pneumoniae using a multiplexed opsonophagocytic killing assay.
Results
Of the 92 patients who underwent randomization, 43 patients in arm A (vaccination 2 weeks before chemotherapy) and 44 patients in arm B (vaccination on the first day of chemotherapy) were analyzed. Immunogenicity was assessed by geometric mean and fold-increase of post-vaccination titers, seroprotection rates (percentage of patients with post-vaccination titers > 1:64), and seroconversion rates (percentage of patients with > 4-fold increase in post-vaccination titers). Serologic responses to PCV13 did not differ significantly between the two study arms according to all three types of assessments.
Conclusion
The overall antibody response to PCV13 is adequate in patients with gastric and colorectal cancer during adjuvant chemotherapy, and no significant difference was found when patients were vaccinated two weeks before or on the day of chemotherapy initiation.

Citations

Citations to this article as recorded by

Long-term Immunogenicity of the 13-valent Pneumococcal Conjugate Vaccine during Adjuvant Chemotherapy in Patients with Gastric and Colorectal Cancer: A 5-Year Follow-up of a Randomized Controlled Trial
Hyeon-Jong Kim, Hyunjin Bang, Hyun-Jung Shim, Jun Eul Hwang, Sang-Hee Cho, Ik-Joo Chung, Seung Ji Kang, Jong Gwang Kim, Seung-Hoon Beom, A-Yeung Jang, Joon Young Song, Woo Kyun Bae
Cancer Research and Treatment.2026; 58(1): 61. CrossRef
Vaccination Against Respiratory Infections in Adults with Cancer: A Concise Guide for Clinicians
Kay Choong See
Vaccines.2026; 14(1): 105. CrossRef
Vaccination in Oncology Patients: Evidence, Clinical Challenges, and Future Directions
Alberto Giuseppe Agostara, Silvia Della Torre, Sara Di Bella, Michela Pelliccione, Paola Candido, Valeria Smiroldo, Laura Roazzi, Gabriele Ciarlo, Davide Toniolo, Francesca Zannier, Roberto Bollina
Vaccines.2026; 14(3): 250. CrossRef
Vaccination of people with solid tumors and diabetes: existing evidence and recommendations. A position statement from a multidisciplinary panel of scientific societies
Marco Gallo, Angioletta Lasagna, Valerio Renzelli, Lelio Morviducci, Alessio Cortellini, Matteo Monami, Giampiero Marino, Stefania Gori, Matteo Verzé, Alberto Ragni, Enzo Tuveri, Laura Sciacca, Stella D’Oronzo, Dario Giuffrida, Annalisa Natalicchio, Franc
Journal of Endocrinological Investigation.2025; 48(8): 1717. CrossRef
Italian oncologists and vaccinations against infectious diseases: Results of a survey of the Italian Association of Medical Oncology
Angioletta Lasagna, Antonella Brunello, Nicola Silvestris, Paolo Pedrazzoli, Massimo Di Maio, Saverio Cinieri
Tumori Journal.2024; 110(1): 60. CrossRef
Vaccination of Adults With Cancer: ASCO Guideline
Mini Kamboj, Kari Bohlke, Deana M. Baptiste, Kieron Dunleavy, Abbey Fueger, Lee Jones, Amar H. Kelkar, Lisa Y. Law, Kristine B. LeFebvre, Per Ljungman, Eric D. Miller, Larissa A. Meyer, Heather N. Moore, Heloisa P. Soares, Randy A. Taplitz, Edom S. Woldet
Journal of Clinical Oncology.2024; 42(14): 1699. CrossRef
Cancer bronchopulmonaire
M. Lachâtre, A. Lemaitre, C. Charlier, J. Mazières
Revue des Maladies Respiratoires Actualités.2024; 16: e39. CrossRef
Vaccination for seasonal influenza, pneumococcal infection and SARS-CoV-2 in patients with solid tumors: recommendations of the Associazione Italiana di Oncologia Medica (AIOM)
P. Pedrazzoli, A. Lasagna, I. Cassaniti, A. Piralla, A. Squeri, R. Bruno, P. Sacchi, F. Baldanti, M. Di Maio, G.D. Beretta, S. Cinieri, N. Silvestris
ESMO Open.2023; 8(3): 101215. CrossRef
Pneumococcal Vaccination in Adults: A Narrative Review of Considerations for Individualized Decision-Making
Kay Choong See
Vaccines.2023; 11(5): 908. CrossRef
Uptake of vaccination in older Indian patients with cancer: A cross-sectional observational study
Tabitha M. Sabu, Vanita Noronha, Abhijith R. Rao, Anita Kumar, Shreya Gattani, Anant Ramaswamy, Anupa Pillai, Ratan Dhekale, Renita Castelino, Sharath Kumar, Arshiya Sehgal, Pallavi Rana, Vikram Gota, Rajendra Badwe, Kumar Prabhash
Cancer Research, Statistics, and Treatment.2023; 6(1): 52. CrossRef
Review of Vaccination Recommendations in Guidelines for Non-Communicable Diseases with Highest Global Disease Burden among Adults 75 Years Old and Above
Abdul Rahman Ishak, Yu Chun Hsieh, Harshitha Srinivasan, Kay Choong See
Vaccines.2023; 11(6): 1076. CrossRef
Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study
Melissa Bersanelli, Elena Verzoni, Alessio Cortellini, Raffaele Giusti, Lorenzo Calvetti, Paola Ermacora, Marilena Di Napoli, Annamaria Catino, Valentina Guadalupi, Giorgia Guaitoli, Vieri Scotti, Francesca Mazzoni, Antonello Veccia, Pamela Francesca Gugl
eClinicalMedicine.2023; 61: 102044. CrossRef
Immunological Assessment of Recent Immunotherapy for Colorectal Cancer
Subhadeep Das, Diptikanta Acharya
Immunological Investigations.2023; 52(8): 1065. CrossRef
Vaccination anti-infectieuse : pour qui ? Quand ? Comment ?
M. Lachâtre, M. Murris-Espin, J. Mazières
Revue des Maladies Respiratoires Actualités.2023; 15(2): 2S209. CrossRef
Predictive biomarkers and specific immune responses of COVID-19 mRNA vaccine in patients with cancer: prospective results from the CACOV-VAC trial
Laurie Spehner, Emeline Orillard, Antoine Falcoz, Quentin Lepiller, Adeline Bouard, Hamadi Almotlak, Stefano Kim, Elsa Curtit, Guillaume Meynard, Marine Jary, Charlee Nardin, Kamal Asgarov, Syrine Abdeljaoued, Ugo Chartral, Virginie Mougey, Myriam Ben Khe
BMJ Oncology.2023; 2(1): e000054. CrossRef
Novel Pneumococcal Protein-Polysaccharide Conjugate Vaccine Based on Biotin-Streptavidin
Mengze Guo, Xiaonan Guo, Chenxing Zhang, Shidong Zhu, Yue Zhang, Tiejun Gu, Wei Kong, Yongge Wu, Nancy E. Freitag
Infection and Immunity.2022;[Epub] CrossRef
COVID-19 vaccination in cancer patients: a narrative review
Suranjith L Seneviratne, Pamodh Yasawardene, Widuranga Wijerathne, Buddhika Somawardana
Journal of International Medical Research.2022;[Epub] CrossRef
Invasive pneumococcal disease among adults with hematological and solid organ malignancies: A population-based cohort study
Hannah M. Garcia Garrido, Mirjam J. Knol, Jarom Heijmans, Nina M. van Sorge, Elisabeth A.M. Sanders, Heinz-Josef Klümpen, Martin P. Grobusch, Abraham Goorhuis
International Journal of Infectious Diseases.2021; 106: 237. CrossRef
Can Cancer Survivors Donate Convalescent Plasma for the Treatment of COVID-19?
Ajit Venniyoor
Indian Journal of Medical and Paediatric Oncology.2021; 42(01): 021. CrossRef
Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment
M. Peeters, L. Verbruggen, L. Teuwen, G. Vanhoutte, S. Vande Kerckhove, B. Peeters, S. Raats, I. Van der Massen, S. De Keersmaecker, Y. Debie, M. Huizing, P. Pannus, K. Neven, K.K. Ariën, G.A. Martens, M. Van Den Bulcke, E. Roelant, I. Desombere, S. Angui
ESMO Open.2021; 6(5): 100274. CrossRef
Recent Topics of Pneumococcal Vaccination: Indication of Pneumococcal Vaccine for Individuals at a Risk of Pneumococcal Disease in Adults
Nobuhiro Asai, Hiroshige Mikamo
Microorganisms.2021; 9(11): 2342. CrossRef
Vaccination practices, efficacy, and safety in adults with cancer
Laboni Sarkar, Vasu Babu Goli, Nandini Menon, Vijay Maruti Patil, Vanita Noronha, Kumar Prabhash
Cancer Research, Statistics, and Treatment.2021; 4(3): 505. CrossRef
Incidence of Invasive Pneumococcal Disease Among Adults With Hematological and Solid Organ Malignancies in the Netherlands: A Population Based Cohort Study
Hannah M. Garcia Garrido, Mirjam J. Knol, J. Heijmans, Nina M. van Sorge, Elisabeth A.M. Sanders, Heinz-Josef Klümpen, Martin P. Grobusch, Abraham Goorhuis
SSRN Electronic Journal .2020;[Epub] CrossRef

10,804 View
285 Download
20 Web of Science
23 Crossref

The Prognostic Significance of FGFR4 Gly388 Polymorphism in Esophageal Squamous Cell Carcinoma after Concurrent Chemoradiotherapy: Hyun-Jeong Shim, Min-Ho Shin, Hee-Nam Kim, Jo-Heon Kim, Jun-Eul Hwang, Woo-Kyun Bae, Ik-Joo Chung, Sang-Hee Cho; Cancer Res Treat. 2016;48(1):71-79. Published online May 14, 2015; DOI: https://doi.org/10.4143/crt.2015.018

Abstract PDF PubReader ePub

Purpose
The purpose of this study is to investigate the role of fibroblast growth factor receptor 4 (FGFR4) polymorphism in esophageal cancer after chemoradiotherapy (CRT).
Materials and Methods
Peripheral blood samples from 244 patients treated with CRT for esophageal squamous cell carcinoma were assessed for the role of FGFR4 genotype on treatment response and survival.
Results
A total of 94 patients were homozygous for the Gly388 allele, and 110 were heterozygous and 40 homozygous for the Arg388 allele. No significant association was found between the FGFR4 genotype and clinicopathological parameters. However, patients carrying the Gly388 allele showed a better overall response rate than Arg388 carriers (p=0.038). In addition, Gly388 allele patients at an earlier stage showed better overall survival (OS) and progression-free survival than Arg388 carriers. Among these, the Gly388 allele showed significantly improved OS compared to Arg388 carriers in the lymph node (LN) metastasis group (p=0.042) compared to the no LN metastasis group (p=0.125). However, similar survival outcomes were observed for advanced-stage disease regardless of genotype.
Conclusion
This result suggests that the role of FGFR4 Gly388 in treatment outcomes differs according to esophageal cancer stage. It showed a predictive role in the response of esophageal cancer patients to CRT with a better trend for OS in Gly388 than Arg388 carriers in the early stages. In particular, LN-positive early-stage patients carrying the Gly388 allele showed improved OS compared to those carrying Arg388.

Citations

Citations to this article as recorded by

Expression of FGF8, FGF18, and FGFR4 in Gastroesophageal Adenocarcinomas
Gerd Jomrich, Xenia Hudec, Felix Harpain, Daniel Winkler, Gerald Timelthaler, Thomas Mohr, Brigitte Marian, Sebastian F. Schoppmann
Cells.2019; 8(9): 1092. CrossRef
Association of Fibroblast Growth Factor Receptor 4 Genetic Polymorphisms With the Development of Uterine Cervical Cancer and Patient Prognosis
Tze-Ho Chen, Shun-Fa Yang, Yu-Fan Liu, Wea-Lung Lin, Chih-Ping Han, Po-Hui Wang
Reproductive Sciences.2018; 25(1): 86. CrossRef
Prognostic implications of fibroblast growth factor receptor 4 polymorphisms in primary breast cancer
Wei Wei, Zilong You, Shanshan Sun, Yuhang Wang, Xianyu Zhang, Da Pang, Yongdong Jiang
Molecular Carcinogenesis.2018; 57(8): 988. CrossRef
FGFR4 Arg388 Is Correlated with Poor Survival in Resected Colon Cancer Promoting Epithelial to Mesenchymal Transition
Sang Hee Cho, Chang Soo Hong, Hee Nam Kim, Min Ho Shin, Ka Rham Kim, Hyun Jeong Shim, Jun Eul Hwang, Woo Kyun Bae, Ik Joo Chung
Cancer Research and Treatment.2017; 49(3): 766. CrossRef
Association between FGFR4 gene polymorphism and high-risk HPV infection cervical cancer
Ya-Ping Li, Lin Zhang, Yu-Liang Zou, Yan Yu
Asian Pacific Journal of Tropical Medicine.2017; 10(7): 680. CrossRef
Identification of NCCRP1 as an epigenetically regulated tumor suppressor and biomarker for malignant phenotypes of squamous cell carcinoma of the esophagus
Takashi Miwa, Mitsuro Kanda, Masahiko Koike, Naoki Iwata, Haruyoshi Tanaka, Shinichi Umeda, Chie Tanaka, Daisuke Kobayashi, Masamichi Hayashi, Suguru Yamada, Tsutomu Fujii, Michitaka Fujiwara, Yasuhiro Kodera
Oncology Letters.2017; 14(4): 4822. CrossRef
Roles of FGFR in oral carcinogenesis
Xiaoyan Xie, Zhiyong Wang, Fangman Chen, Yao Yuan, Jiayi Wang, Rui Liu, Qianming Chen
Cell Proliferation.2016; 49(3): 261. CrossRef
Predictive role of Host Constitutive Variants in Neoadjuvant Therapy of Esophageal Cancer
Enrica Rumiato, Elisa Boldrin, Alberto Amadori, Daniela Saggioro
Pharmacogenomics.2016; 17(7): 805. CrossRef
Adherens junctions associated protein 1 serves as a predictor of recurrence of squamous cell carcinoma of the esophagus
Haruyoshi Tanaka, Mitsuro Kanda, Masahiko Koike, Naoki Iwata, Dai Shimizu, Kazuhiro Ezaka, Satoshi Sueoka, Yuri Tanaka, Hideki Takami, Ryoji Hashimoto, Chie Tanaka, Suguru Yamada, Tsutomu Fujii, Goro Nakayama, Hiroyuki Sugimoto, Michitaka Fujiwara, Yasuhi
International Journal of Oncology.2015;[Epub] CrossRef

14,307 View
79 Download
12 Web of Science
9 Crossref

First
Prev
Page of 1
Next
Last

Search